SSI-4
Based on 1 Customer Validation
SSI-4 is an orally active stearoyl-CoA desaturase (SCD1) inhibitor with an EC50 of 1.9 nM against mouse SCD1. SSI-4 blocks the conversion of saturated fatty acids to monounsaturated fatty acids, reducing the production of oleic acid and palmitoleic acid. SSI-4 induces lipid peroxidation, endoplasmic reticulum stress, DNA damage and activates apoptotic mechanisms. SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. SSI-4 is applicable to research on cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.99%
- CAS No.: 1875084-68-6
- Formule: C19H21ClN4O3
- Masse moléculaire:388.85
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
SCD1[1]
SSI-4 (1 μM; 21 d) inhibits the proliferation of human acute myeloid leukemia (AmL) cell lines MOLM-13, MV-4-11 and OCI-AmL3, with differential activity observed across these cell lines[1].
SSI-4 (0.01-10 μM; 72 h) induces dose-dependent cell death in sensitive human acute myeloid leukemia cell lines K562, MOLM-13, and MV-4-11, but exerts no such effect in resistant human acute myeloid leukemia cell lines OCI-AmL3, THP-1, HL-60, Kasumi-1, and TF-1[1].
SSI-4 (1-10 μM; 4-7 d) induces cell death in primary samples from a subset of human AmL patients, and its sensitivity is independent of specific driver mutations[1].
SSI-4 (1 μM; 24 h) inhibits de novo monounsaturated fatty acid (MUFA) biosynthesis and increases the accumulation of saturated fatty acid (SFA) in the sensitive human acute myeloid leukemia cell lines MOLM-13 and MV-4-11, but exerts minimal effects on fatty acid biosynthesis in the drug-resistant OCI-AmL3 cells[1].
SSI-4 (1 μM; 24 h) significantly increases the SFA/MUFA ratio in sensitive human acute myeloid leukemia cell lines K562, MOLM-13 and MV-4-11, but exerts no such effect on drug-resistant human acute myeloid leukemia cell lines OCI-AmL3, THP-1 and HL-60[1].
SSI-4 (1 μM; 24 h) induces lipid peroxidation in sensitive human acute myeloid leukemia (AmL) cell lines K562, MOLM-13 and MV-4-11, but exerts no such effect in drug-resistant human AmL cell lines OCI-AmL3, THP-1, HL-60 and Kasumi-1[1].
SSI-4 (1 μM; 72 h) induces early apoptosis in the human AmL cell line MOLM-13[1].
When used in combination with palmitic acid, SSI-4 (1 μM; 72 h) activates apoptotic mechanisms in both the sensitive human acute myeloid leukemia cell line MOLM-13 and the drug-resistant human acute myeloid leukemia cell line OCI-AmL3[1].
SSI-4 (1 μM; 72 h) induces apoptosis in the sensitive human acute myeloid leukemia (AmL) cell lines MOLM-13 and MV-4-11, and this effect is partially reversed by pan-caspase inhibition[1].
SSI-4 (1 μM; 24 h) induces mild DNA damage in the human AmL cell line MV-4-11 and enhances palmitic acid- or doxorubicin-induced DNA damage[1].
SSI-4 (0-1000 nM; 72 h) acts synergistically with doxorubicin to reduce the viability of the human acute myeloid leukemia cell line MV-4-11[1].
SSI-4 inhibits stearoyl-CoA desaturase-mediated monounsaturated fatty acid accumulation in LPS/IL-4 activated mouse B cells[2].
SSI-4 (48 h) blocks de novo glucose synthesis of monounsaturated fatty acids in activated mouse B cells[2].
SSI-4 (1 μM; 3 d) dose-dependently inhibits the proliferation of mouse B cells activated by LPS/IL-4 and reduces cell viability at 72 h, while exogenous oleic acid reverses these effects[2].
SSI-4 (3 d) inhibits the proliferation of mouse B cells activated by anti-IgM/anti-CD40/IL-4 or CpG/IL-4/IL-5, and this effect is reversible by exogenous oleic acid[2].
SSI-4 (3 d) inhibits IgG1 class switching in mouse B cells activated by LPS/IL-4, and this effect is reversed by exogenous oleic acid[2].
SSI-4 inhibits the proliferation of activated human B cells, and this effect can be reversed by exogenous oleic acid[2].
SSI-4 reduces the expression of CD80 and CD86 on activated human B cells, and this effect can be reversed by exogenous oleic acid[2].
SSI-4 impairs the metabolic adaptability of activated mouse B cells by simultaneously reducing the levels of oxidative phosphorylation and glycolysis[2].
SSI-4 induces excessive autophagosome formation in activated mouse B cells[2].
SSI-4 induces autophagy, inhibits mTORC1 activity (decreased p-S6 level), and downregulates AID expression in activated mouse B cells, while all these effects are reversed by exogenous oleic acid[2].
SSI-4 induces endoplasmic reticulum stress in activated mouse B cells, and this effect is reversed by exogenous oleic acid[2].
SSI-4 potently blocks the conversion of saturated fatty acids to monounsaturated fatty acids in mouse liver microsomes, with an EC50 of 1.9 nM[3].
SSI-4 (0.001-0.009 μM; 72 h) potently inhibits the proliferation of ccRCC cell lines A498, ACHN, Caki1 and Caki2, with IC50 values ranging from 0.001 to 0.009 μM[4].
SSI-4 (0.001-0.009 μM) upregulates BiP and CHOP, specific markers of the stearoyl-CoA desaturase 1 (SCD1)-dependent unfolded protein response, in A498 and ACHN cells, and this effect is reversed by oleic acid supplementation[4].
SSI-4 (10-100 nM) exhibits high kinome selectivity, with no off-target kinase binding at 10 nM, and only binds to CDKL2 at 100 nM[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human acute myeloid leukemia AML cell lines MOLM-13, MV-4-11, OCI-AML3
-
Concentration:1 μM
-
Incubation Time:6 cycles of 72 h over 21 days total
-
Result:Reduced cumulative cell divisions in all three cell lines tested, with the strongest inhibition observed in MOLM-13 cells, followed by MV-4-11 cells, and the weakest inhibition in OCI-AML3 cells.
-
Cell Line:human AML cell line MOLM-13
-
Concentration:1 μM
-
Incubation Time:72 h
-
Result:Significantly increased early apoptosis in MOLM-13 cells.
-
Cell Line:human AML cell lines MOLM-13, OCI-AML3
-
Concentration:1 μM
-
Incubation Time:72 h
-
Result:Induced cleavage of PARP and caspase 3 in both MOLM-13 and resistant OCI-AML3 cells grown in the presence of palmitate.
-
Cell Line:human AML cell lines MOLM-13, MV-4-11
-
Concentration:1 μM
-
Incubation Time:72 h
-
Result:Induced cell death in both MOLM-13 and MV-4-11 cells, with partial rescue observed when co-treated with pan-caspase inhibitor Q-VD-OPh, though the effect was not fully abrogated.
SSI-4 (10 mg/kg; p.o.; once daily; for 14 consecutive days) significantly reduces bone marrow leukemia burden in two patient-derived xenograft models of acute myeloid leukemia in NBSGW mice[1].
SSI-4 (30 mg/kg; p.o.; once daily for 1 consecutive week) impairs the early development of B cells in mouse bone marrow, inhibits germinal center formation and immune-induced antigen-specific IgG/IgG1 production; in the influenza infection model of C57BL/6 mice, this agent also suppresses the formation of antiviral germinal centers and the production of IgG/IgG1/IgG2c, while exacerbating weight loss in mice[2].
SSI-4 (60-600 mg/kg; p.o.; consecutive administration; 4.5 weeks) dose-dependently inhibits the growth of subcutaneously inoculated A498 clear cell renal cell carcinoma tumors in athymic nude mice[4].
SSI-4 (20 mg/kg; p.o.; consecutive dosing; 28 days) significantly reduces the pulmonary metastatic tumor burden of ACHN clear cell renal cell carcinoma in athymic nude mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NBSGW[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; daily; 9 days
-
Result:Significantly prolonged overall survival of mice compared to controls, with a marked separation in survival curves starting around day 30.
-
Animal Model:NBSGW[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Caused a significant decrease in relative BM leukemia burden in both PDX models, with a more pronounced effect observed in one of the two samples.\n
Induced lipid peroxidation in leukemic cells from treated mice in both models.
-
Animal Model:C57BL/6 (2-4 months old, both sexes)[2]
-
Dosage:30 mg/kg
-
Administration:oral; daily continuous via chow; 1 week (maintained during immunization or infection period as applicable)
-
Result:Reduced frequencies of immature B cells, CD19+B220int B cell precursors, and CD25+ pre-B cells in bone marrow; slightly increased mature B cell frequency in peripheral tissues; showed no effect on thymocyte, peripheral CD4+ T cell, or mature peripheral B cell composition.\n
Reduced serum oleic acid and palmitoleic acid content; reduced germinal center B cell frequency from 5.68% to 2.52% and NP+ germinal center B cell frequency from 33.6% to 17.4%; showed no effect on B220intCD138+ plasmablast or PD-1+CXCR5+ Tfh cell frequencies; reduced serum anti-NP IgG.\n
Caused more severe weight loss
-
Animal Model:Athymic nude mice[4]
-
Dosage:60 mg/kg; 180 mg/kg; 600 mg/kg
-
Administration:oral (incorporated into chow); continuous; 4.5 weeks
-
Result:Produced dose-dependent inhibition of A498 tumor growth.
-
Animal Model:Athymic nude mice[4]
-
Dosage:180 mg/kg (stated); 20 mg/kg (effective, corrected for altered consumption)
-
Administration:oral (incorporated into chow); continuous; 28 days
-
Result:Reduced mean total lung bioluminescent flux.
Reduced mean lesion width of metastatic nodules.
Chemical Information
-
CAS No. 1875084-68-6
-
Appearance Solid
-
Masse moléculaire 388.85
-
Formule C19H21ClN4O3
-
Color White to off-white
-
SMILES
O=C(NC)C1=CC(NC(N2CCC(OC3=CC=CC=C3Cl)CC2)=O)=NC=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (257.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.43 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.43 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (289 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Dembitz V, et al. Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation. Leukemia. 2024;38(11):2395-2409. [Content Brief]
[2]. Zhou X, et al. Stearoyl-CoA Desaturase-Mediated Monounsaturated Fatty Acid Availability Supports Humoral Immunity. Cell Rep. 2021;34(1):108601. [Content Brief]
[3]. Li KP, et al. Radiosynthesis and Preliminary Evaluation of [11C]SSI-4 for the Positron Emission Tomography Imaging of Stearoyl CoA Desaturase 1. Mol Pharm. 2023;20(8):4129-4137. [Content Brief]
[4]. von Roemeling CA, et al. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 2017;9(1):3-20. Published 2017 Oct 6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5717 mL | 12.8584 mL | 25.7169 mL | 64.2921 mL |
| 5 mM | 0.5143 mL | 2.5717 mL | 5.1434 mL | 12.8584 mL | |
| 10 mM | 0.2572 mL | 1.2858 mL | 2.5717 mL | 6.4292 mL | |
| 15 mM | 0.1714 mL | 0.8572 mL | 1.7145 mL | 4.2861 mL | |
| 20 mM | 0.1286 mL | 0.6429 mL | 1.2858 mL | 3.2146 mL | |
| 25 mM | 0.1029 mL | 0.5143 mL | 1.0287 mL | 2.5717 mL | |
| 30 mM | 0.0857 mL | 0.4286 mL | 0.8572 mL | 2.1431 mL | |
| 40 mM | 0.0643 mL | 0.3215 mL | 0.6429 mL | 1.6073 mL | |
| 50 mM | 0.0514 mL | 0.2572 mL | 0.5143 mL | 1.2858 mL | |
| 60 mM | 0.0429 mL | 0.2143 mL | 0.4286 mL | 1.0715 mL | |
| 80 mM | 0.0321 mL | 0.1607 mL | 0.3215 mL | 0.8037 mL | |
| 100 mM | 0.0257 mL | 0.1286 mL | 0.2572 mL | 0.6429 mL |
SSI-4 Related Classifications
HY-155033 Related Classifications
Powered by Bioz
- SSI-4
- 1875084-68-6
- SSI4
- SSI 4
- Stearoyl-CoA Desaturase (SCD)
- DNA/RNA Synthesis
- Apoptosis
- Autophagy
- mTOR
- Influenza Virus
- MOLM-13
- mouse bone marrow
- MV-4-11
- acute myeloid leukemia
- stearoyl-CoA desaturase (SCD1)
- influenza-infected mice
- patient-derived xenograft models
- hepatocellular carcinoma
- AML cells
- B cells
- Inhibitor
- inhibitor
- inhibit